2023
Synthesizing and Applying Molecular Targeted Imaging Results in Patients With Prostate Cancer (RADAR VII)
Crawford E, Harris R, Slovin S, Concepcion R, Albala D, Gomella L, Orio P, Sellinger S, Petrylak D, Koo P. Synthesizing and Applying Molecular Targeted Imaging Results in Patients With Prostate Cancer (RADAR VII). JU Open Plus 2023, 1 DOI: 10.1097/ju9.00000000000000011.Peer-Reviewed Original ResearchProstate cancerNonmetastatic castrate-resistant prostate cancerClinical decisionCastrate-resistant prostate cancerConventional imagingLimited clinical dataTreatment of patientsFuture clinical trialsTreatment decision makingProstate cancer researchLimited available evidenceNuclear medicine specialistsLocalized diseaseMetastatic diseaseMedical oncologistsProspective studyBiochemical recurrenceClinical trialsRadiographic assessmentClinical dataMore robust recommendationsMedicine specialistsClinical experienceConsensus guidanceRadiation oncologists
2017
Phase 1 study of the PSMA-targeted small-molecule drug conjugate EC1169 in patients with metastatic castrate-resistant prostate cancer (mCRPC).
Morris M, Vogelzang N, Sartor O, Armour A, Groaning M, Robarts A, Petrylak D, Tolcher A, Gordon M, Babiker H. Phase 1 study of the PSMA-targeted small-molecule drug conjugate EC1169 in patients with metastatic castrate-resistant prostate cancer (mCRPC). Journal Of Clinical Oncology 2017, 35: 5038-5038. DOI: 10.1200/jco.2017.35.15_suppl.5038.Peer-Reviewed Original ResearchMetastatic castrate-resistant prostate cancerProstate-specific membrane antigenRadiographic progression-free survivalProstate cancerMedian radiographic progression-free survivalCastrate-resistant prostate cancerProgression-free survivalPhase 1 studySoft tissue diseasePatient selection toolPotential therapeutic targetAnti-tumor activityB ptsMost normal tissuesG3 thrombocytopeniaExpansion cohortPrimary endpointDose escalationMedian ageTissue diseaseRadiographic assessmentMedian numberDisease localizationDose reductionPart B